Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: METTL2B (ImmuneEditome ID:55798)

1. Gene summary of enriched editing regions for METTL2B

Gene summary

Gene information	Gene symbol	METTL2B
	Gene ID	55798
	GeneSynonyms	METL\|METTL2\|METTL2A\|PSENIP1
	GeneCytomap	7q32.1
	GeneType	protein-coding
	GeneDescription	tRNA N(3)-methylcytidine methyltransferase METTL2B\|methyltransferase 2B, methylcytidine\|methyltransferase like 2B\|methyltransferase-like protein 2B
	GeneModificationdate	20230524
	UniprotID	Q6P1Q9;H7C552;F8WAS9
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr7:128481649-128482400:+	ENST00000473488.1	ENSG00000165055.14	METTL2B	ncRNA_intronic	AluJo,AluSx	chr7:128481649-128482400:+.alignment
chr7:128481649-128482400:+	ENST00000482555.4	ENSG00000165055.14	METTL2B	ncRNA_intronic	AluJo,AluSx	chr7:128481649-128482400:+.alignment
chr7:128502640-128506122:+	ENST00000481392.1	ENSG00000165055.14	METTL2B	exonic	AluSq2,L1MC4,AluJr,AluJb,AluJr4,AluSx1,AluSp,AluSc8	chr7:128502640-128506122:+.alignment

Top

2. Tumor-specific enriched editing regions for METTL2B

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr7:128502640-128506122:+	COAD	EER	2.9118e-02
ENSG00000165055.14,METTL2B	COAD	EAG	2.0806e-02
chr7:128502640-128506122:+	HNSC	EER	1.5535e-05
ENSG00000165055.14,METTL2B	HNSC	EAG	1.7008e-05
chr7:128502640-128506122:+	KIRP	EER	3.8769e-02
ENSG00000165055.14,METTL2B	KIRP	EAG	3.9647e-02
chr7:128502640-128506122:+	LIHC	EER	5.6310e-04
ENSG00000165055.14,METTL2B	LIHC	EAG	6.1049e-04
chr7:128502640-128506122:+	LUAD	EER	5.2033e-03
ENSG00000165055.14,METTL2B	LUAD	EAG	5.8057e-03

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000165055.14,METTL2B	BLCA	Path	EAG	2.3055e-02	1.3726e-02	0.1225
chr7:128502640-128506122:+	BLCA	Path	EER	2.0060e-02	1.1783e-02	0.1252
ENSG00000165055.14,METTL2B	THCA	Path	EAG	1.7551e-03	2.4545e-02	0.1004
chr7:128502640-128506122:+	THCA	Path	EER	1.5623e-03	2.4114e-02	0.1006

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for METTL2B

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr7:128502640-128506122:+

LIHC

EER

ENSG00000250722,SEPP1

0.4677

3.3726e-17

5.1899e-16

0.4057

ADAR;AUH;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28A;LIN28B;MBNL2;MOV10;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM27;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_BILE_ACID_METABOLISM

chr7:128502640-128506122:+

COAD

EER

ENSG00000143614,GATAD2B

0.2213

1.0246e-02

3.6559e-18

0.4983

ADAR;AIFM1;AUH;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;MBNL2;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;RTCB;SAFB2;SBDS;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

Eosinophils

GSVA_HALLMARK_XENOBIOTIC_METABOLISM

chr7:128502640-128506122:+

COAD

EER

ENSG00000117523,PRRC2C

0.2074

1.8698e-02

1.9619e-14

0.4457

ADAR;AIFM1;AUH;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;RTCB;SAFB2;SBDS;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

PRRC2C

Eosinophils

GSVA_HALLMARK_DNA_REPAIR

chr7:128502640-128506122:+

COAD

EER

ENSG00000273768,RNU1-1

0.1469

3.2141e-02

8.4197e-13

0.4194

NK_cells_resting

GSVA_HALLMARK_UV_RESPONSE_UP

chr7:128502640-128506122:+

COAD

EER

ENSG00000225972,MTND1P23

-0.1866

3.8275e-02

5.9932e-17

0.4821

Dendritic_cells_activated

GSVA_HALLMARK_UV_RESPONSE_UP

chr7:128502640-128506122:+

COAD

EER

ENSG00000181222,POLR2A

0.1789

4.9431e-02

7.8757e-15

0.4517

AIFM1;AUH;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RTCB;SAFB2;SBDS;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

Dendritic_cells_activated

GSVA_HALLMARK_APICAL_SURFACE

chr7:128502640-128506122:+

DLBC

EER

ENSG00000264577,AC010761.8

-0.6390

5.2241e-03

1.6213e-04

-0.5230

ADAR;EIF4A3

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MYC_TARGETS_V2

chr7:128502640-128506122:+

DLBC

EER

ENSG00000273568,RP11-417L19.6

-0.6045

5.5244e-03

2.0649e-03

-0.4382

DDX42;DDX54;DGCR8;EIF4A3;ELAVL1;FBL;HNRNPC;IGF2BP2;LARP4B;MOV10;NOP56;NOP58;PTBP1;RBM10;SMNDC1;SRSF1;SRSF3;U2AF1;U2AF2;UPF1;YTHDF1

chr7:128502640-128506122:+

DLBC

EER

ENSG00000081087,OSTM1

0.6311

6.4332e-03

9.2317e-04

0.4675

ADAR;AIFM1;AUH;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RTCB;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZNF184

B_cells_memory

GSVA_HALLMARK_MYC_TARGETS_V2

chr7:128502640-128506122:+

DLBC

EER

ENSG00000160917,CPSF4

-0.5789

1.1067e-02

9.4873e-04

-0.4665

Macrophages_M1

GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING

More results

Top

4. Enriched editing regions and immune related splicing for METTL2B

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000165055.14,METTL2B

COAD

EAG

MEX

ENSG00000145495.10

chr5

10394752:10394785:10397292:10397307:10400783:10400842:10402058:10402139

-0.2460

1.5814e-02

1.0951e-13

-0.4318

ADAR;AIFM1;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NCBP3;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

Dendritic_cells_activated

GSVA_HALLMARK_INFLAMMATORY_RESPONSE

ENSG00000165055.14,METTL2B

COAD

EAG

MEX

ENSG00000137500.5

chr11

83265915:83265979:83273646:83273738:83273792:83273864:83273950:83273992

-0.2228

4.1365e-02

4.2468e-14

-0.4382

ADAR;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;GNL3;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;RBM5;RNF219;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZC3H7B;ZNF184

Dendritic_cells_activated

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

ENSG00000165055.14,METTL2B

COAD

EAG

MEX

ENSG00000136986.5

chr8

123015445:123015585:123019194:123019305:123030604:123030716:123041969:123042122

-0.2224

4.8361e-02

2.0735e-20

-0.5236

ADAR;AIFM1;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NCBP3;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

DERL1

Dendritic_cells_activated

GSVA_HALLMARK_DNA_REPAIR

ENSG00000165055.14,METTL2B

COAD

EAG

MEX

ENSG00000145495.10

chr5

10394752:10394785:10397292:10397307:10400837:10400842:10402058:10402139

-0.2457

1.6066e-02

1.2583e-13

-0.4308

Dendritic_cells_activated

GSVA_HALLMARK_INFLAMMATORY_RESPONSE

chr7:128502640-128506122:+

COAD

EER

MEX

ENSG00000169660.11

chr17

82440996:82441075:82441164:82441266:82441820:82441889:82442176:82442352

0.2216

3.9558e-02

1.5025e-12

0.4181

ADAR;AIFM1;AUH;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZNF184

GSVA_HALLMARK_APICAL_SURFACE

ENSG00000165055.14,METTL2B

COAD

EAG

ENSG00000058673.11

chr1

203795659:203795794:203801574:203802261

0.2376

7.2263e-03

1.0691e-12

0.4524

ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NCBP3;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

Eosinophils

GSVA_HALLMARK_PEROXISOME

ENSG00000165055.14,METTL2B

COAD

EAG

ENSG00000136930.8

chr9

124353465:124353709:124356763:124356915

0.2547

1.1289e-02

6.1901e-27

0.5921

ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;LARP4B;LARP7;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;SBDS;SF3A3;SF3B4;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YTHDF1

PSMB7

Eosinophils

GSVA_HALLMARK_DNA_REPAIR

ENSG00000165055.14,METTL2B

COAD

EAG

ENSG00000121716.14

chr7

100345841:100345968:100349730:100349887

0.2103

1.6372e-02

1.8956e-14

0.5113

ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI2;NCBP3;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

Eosinophils

GSVA_HALLMARK_P53_PATHWAY

ENSG00000165055.14,METTL2B

COAD

EAG

ENSG00000115392.7

chr2

58159242:58159800:58160107:58160179

0.2930

1.1611e-03

2.4572e-15

0.4585

ADAR;AIFM1;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;LARP4B;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM47;RBM5;RC3H1;SBDS;SF3A3;SF3B4;SMNDC1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YTHDF1;ZC3H7B;ZNF184

FANCL

Eosinophils

GSVA_HALLMARK_DNA_REPAIR

ENSG00000165055.14,METTL2B

COAD

EAG

MEX

ENSG00000159352.11

chr1

151265165:151265234:151265393:151265532:151266003:151266112:151266307:151266439

0.2390

2.1887e-02

1.5636e-21

0.5366

ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZNF184

PSMD4

Eosinophils

GSVA_HALLMARK_DNA_REPAIR

More results

Top

5. Enriched editing regions and immune infiltration for METTL2B

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr7:128502640-128506122:+	BLCA	EER	Macrophages_M1	4.1474e-07	0.2492
ENSG00000165055.14,METTL2B	BLCA	EAG	Macrophages_M1	3.2314e-07	0.2515
chr7:128502640-128506122:+	BRCA	EER	T_cells_CD4_memory_resting	2.4641e-06	0.1429
ENSG00000165055.14,METTL2B	BRCA	EAG	T_cells_CD4_memory_resting	4.6380e-07	0.1525
chr7:128502640-128506122:+	CESC	EER	Macrophages_M0	2.6729e-03	0.1722
ENSG00000165055.14,METTL2B	CESC	EAG	Macrophages_M0	2.5590e-03	0.1730
chr7:128502640-128506122:+	CHOL	EER	T_cells_CD4_naive	1.9792e-02	0.3922
ENSG00000165055.14,METTL2B	CHOL	EAG	T_cells_CD4_naive	1.9792e-02	0.3922
chr7:128502640-128506122:+	COAD	EER	Dendritic_cells_activated	1.0506e-02	0.1564
ENSG00000165055.14,METTL2B	COAD	EAG	Dendritic_cells_activated	1.8474e-04	0.2256
chr7:128502640-128506122:+	DLBC	EER	NK_cells_activated	3.2058e-03	0.4211
ENSG00000165055.14,METTL2B	DLBC	EAG	NK_cells_activated	3.8833e-03	0.4133
chr7:128502640-128506122:+	ESCA	EER	Macrophages_M2	6.8979e-04	0.2647
ENSG00000165055.14,METTL2B	ESCA	EAG	T_cells_regulatory_(Tregs)	4.2490e-03	-0.2242
chr7:128502640-128506122:+	GBM	EER	T_cells_CD4_memory_resting	1.2271e-03	0.2481
ENSG00000165055.14,METTL2B	GBM	EAG	T_cells_CD4_memory_resting	1.4585e-03	0.2444
chr7:128502640-128506122:+	HNSC	EER	Macrophages_M2	5.1340e-03	-0.1264
ENSG00000165055.14,METTL2B	HNSC	EAG	Macrophages_M2	5.0985e-03	-0.1265
chr7:128502640-128506122:+	KICH	EER	Dendritic_cells_resting	2.3413e-02	0.2809
ENSG00000165055.14,METTL2B	KICH	EAG	Dendritic_cells_resting	2.3413e-02	0.2809
chr7:128502640-128506122:+	KIRC	EER	T_cells_follicular_helper	2.2655e-03	-0.1562
ENSG00000165055.14,METTL2B	KIRC	EAG	T_cells_follicular_helper	3.0584e-03	-0.1516
chr7:128502640-128506122:+	KIRP	EER	T_cells_CD4_memory_resting	2.5777e-02	-0.1321
ENSG00000165055.14,METTL2B	KIRP	EAG	T_cells_CD4_memory_resting	3.1655e-02	-0.1273
chr7:128502640-128506122:+	LGG	EER	T_cells_gamma_delta	4.7983e-05	0.1758
ENSG00000165055.14,METTL2B	LGG	EAG	T_cells_gamma_delta	4.7617e-05	0.1759
chr7:128502640-128506122:+	LIHC	EER	T_cells_regulatory_(Tregs)	4.0145e-05	-0.2124
ENSG00000165055.14,METTL2B	LIHC	EAG	T_cells_regulatory_(Tregs)	4.4685e-05	-0.2111
chr7:128502640-128506122:+	LUAD	EER	T_cells_CD4_memory_resting	4.7417e-06	0.2022
ENSG00000165055.14,METTL2B	LUAD	EAG	T_cells_CD4_memory_resting	9.8425e-06	0.1953
chr7:128502640-128506122:+	LUSC	EER	NK_cells_resting	1.2326e-03	0.1457
ENSG00000165055.14,METTL2B	LUSC	EAG	NK_cells_resting	6.2385e-04	0.1540
chr7:128502640-128506122:+	OV	EER	T_cells_CD8	1.8129e-02	0.1382
ENSG00000165055.14,METTL2B	OV	EAG	T_cells_CD8	3.1148e-02	0.1262
chr7:128502640-128506122:+	PRAD	EER	T_cells_CD4_memory_resting	5.2834e-03	0.1252
ENSG00000165055.14,METTL2B	PRAD	EAG	T_cells_CD4_memory_resting	8.7675e-03	0.1177
chr7:128502640-128506122:+	READ	EER	T_cells_gamma_delta	2.0173e-03	0.3129
ENSG00000165055.14,METTL2B	READ	EAG	T_cells_gamma_delta	2.0173e-03	0.3129
chr7:128502640-128506122:+	SARC	EER	Plasma_cells	4.6318e-03	0.1768
ENSG00000165055.14,METTL2B	SARC	EAG	Plasma_cells	4.2807e-03	0.1783
chr7:128502640-128506122:+	SKCM	EER	T_cells_CD8	2.3014e-02	0.1052
ENSG00000165055.14,METTL2B	SKCM	EAG	T_cells_CD8	2.4081e-02	0.1044
chr7:128502640-128506122:+	STAD	EER	Eosinophils	3.7245e-04	0.1843
ENSG00000165055.14,METTL2B	STAD	EAG	Eosinophils	2.7982e-04	0.1881
chr7:128502640-128506122:+	TGCT	EER	B_cells_naive	1.7439e-02	0.1901
ENSG00000165055.14,METTL2B	TGCT	EAG	B_cells_naive	1.9795e-02	0.1864
chr7:128502640-128506122:+	THCA	EER	Dendritic_cells_activated	1.1602e-02	0.1125
ENSG00000165055.14,METTL2B	THCA	EAG	NK_cells_resting	1.3297e-02	-0.1103
chr7:128502640-128506122:+	THYM	EER	T_cells_regulatory_(Tregs)	1.8677e-05	-0.3830
ENSG00000165055.14,METTL2B	THYM	EAG	T_cells_regulatory_(Tregs)	1.8946e-05	-0.3827
chr7:128502640-128506122:+	UCEC	EER	B_cells_naive	4.3205e-02	0.1530
ENSG00000165055.14,METTL2B	UCEC	EAG	T_cells_CD4_memory_resting	5.8739e-03	0.2069
chr7:128502640-128506122:+	UCS	EER	Eosinophils	1.8091e-02	-0.3149
ENSG00000165055.14,METTL2B	UCS	EAG	Eosinophils	1.7348e-02	-0.3168

Top

6. Enriched editing regions and immune gene sets for METTL2B

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
chr7:128502640-128506122:+	BLCA	EER	1.5540e-03	0.1573	1.9492e-03	0.1541	4.6790e-03	0.1408	1.0548e-04	0.1922
ENSG00000165055.14,METTL2B	BLCA	EAG	1.5536e-03	0.1573	2.0920e-03	0.1530	5.1877e-03	0.1392	8.4204e-05	0.1948
chr7:128502640-128506122:+	LIHC	EER	1.4013e-03	-0.1659	8.2328e-03	-0.1376	1.0730e-03	-0.1698	3.2513e-02	0.1115
ENSG00000165055.14,METTL2B	LIHC	EAG	1.9796e-03	-0.1607	1.1199e-02	-0.1321	1.4063e-03	-0.1659	3.7379e-02	0.1086
chr7:128502640-128506122:+	UCEC	EER	2.8531e-03	0.2242	3.4925e-03	0.2196	3.6393e-03	0.2187	1.7090e-04	0.2804

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr7:128502640-128506122:+	ACC	GSVA_HALLMARK_HYPOXIA	EER	3.8680e-02	0.2409
ENSG00000165055.14,METTL2B	ACC	GSVA_HALLMARK_P53_PATHWAY	EAG	3.1687e-02	0.2500
chr7:128502640-128506122:+	BLCA	GSVA_HALLMARK_UV_RESPONSE_DN	EER	1.1594e-07	0.2606
ENSG00000165055.14,METTL2B	BLCA	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	1.3804e-07	0.2590
ENSG00000165055.14,METTL2B	BRCA	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	1.5609e-11	0.2031
chr7:128502640-128506122:+	BRCA	GSVA_HALLMARK_UV_RESPONSE_DN	EER	3.4131e-12	0.2098
chr7:128502640-128506122:+	CESC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	1.1521e-06	0.2756
ENSG00000165055.14,METTL2B	CESC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.5290e-06	0.2725
chr7:128502640-128506122:+	CHOL	GSVA_HALLMARK_MYC_TARGETS_V2	EER	6.8073e-03	-0.4491
ENSG00000165055.14,METTL2B	CHOL	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	6.8073e-03	-0.4491
chr7:128502640-128506122:+	COAD	GSVA_HALLMARK_DNA_REPAIR	EER	1.6313e-03	-0.1919
ENSG00000165055.14,METTL2B	COAD	GSVA_HALLMARK_DNA_REPAIR	EAG	2.1851e-05	-0.2552
chr7:128502640-128506122:+	DLBC	GSVA_HALLMARK_MYC_TARGETS_V2	EER	1.2632e-03	-0.4564
ENSG00000165055.14,METTL2B	DLBC	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	2.2186e-03	-0.4355
ENSG00000165055.14,METTL2B	ESCA	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	5.8483e-03	-0.2163
chr7:128502640-128506122:+	ESCA	GSVA_HALLMARK_HYPOXIA	EER	8.7633e-03	0.2060
chr7:128502640-128506122:+	GBM	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	1.7722e-02	0.1833
ENSG00000165055.14,METTL2B	GBM	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EAG	2.1598e-02	0.1777
ENSG00000165055.14,METTL2B	HNSC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	4.7693e-09	-0.2608
chr7:128502640-128506122:+	HNSC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	4.3470e-09	-0.2615
ENSG00000165055.14,METTL2B	KICH	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EAG	7.7367e-03	0.3275
chr7:128502640-128506122:+	KICH	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EER	7.7367e-03	0.3275
ENSG00000165055.14,METTL2B	KIRC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.3062e-04	0.1950
chr7:128502640-128506122:+	KIRC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	1.2223e-04	0.1958
chr7:128502640-128506122:+	KIRP	GSVA_HALLMARK_PROTEIN_SECRETION	EER	2.3513e-06	0.2754
ENSG00000165055.14,METTL2B	KIRP	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	3.0722e-06	0.2723
ENSG00000165055.14,METTL2B	LGG	GSVA_HALLMARK_DNA_REPAIR	EAG	5.1214e-04	-0.1505
chr7:128502640-128506122:+	LGG	GSVA_HALLMARK_DNA_REPAIR	EER	4.7646e-04	-0.1514
chr7:128502640-128506122:+	LIHC	GSVA_HALLMARK_HEME_METABOLISM	EER	3.2107e-12	0.3527
ENSG00000165055.14,METTL2B	LIHC	GSVA_HALLMARK_HEME_METABOLISM	EAG	6.2941e-12	0.3482
ENSG00000165055.14,METTL2B	LUAD	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	4.7772e-08	0.2400
chr7:128502640-128506122:+	LUAD	GSVA_HALLMARK_UV_RESPONSE_DN	EER	5.3361e-08	0.2394
chr7:128502640-128506122:+	LUSC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	5.3858e-05	0.1816
ENSG00000165055.14,METTL2B	LUSC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	6.0606e-05	0.1802
chr7:128502640-128506122:+	MESO	GSVA_HALLMARK_DNA_REPAIR	EER	5.2396e-04	-0.3747
ENSG00000165055.14,METTL2B	MESO	GSVA_HALLMARK_DNA_REPAIR	EAG	5.1100e-04	-0.3754
chr7:128502640-128506122:+	OV	GSVA_HALLMARK_DNA_REPAIR	EER	2.8059e-03	0.1743
ENSG00000165055.14,METTL2B	OV	GSVA_HALLMARK_DNA_REPAIR	EAG	6.5884e-03	0.1587
ENSG00000165055.14,METTL2B	PAAD	GSVA_HALLMARK_ANGIOGENESIS	EAG	9.0815e-04	0.2493
chr7:128502640-128506122:+	PAAD	GSVA_HALLMARK_ANGIOGENESIS	EER	8.3949e-04	0.2509
ENSG00000165055.14,METTL2B	PCPG	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	1.9552e-07	0.3732
chr7:128502640-128506122:+	PCPG	GSVA_HALLMARK_PROTEIN_SECRETION	EER	2.0605e-07	0.3726
ENSG00000165055.14,METTL2B	PRAD	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	1.0767e-05	0.1964
chr7:128502640-128506122:+	PRAD	GSVA_HALLMARK_UV_RESPONSE_DN	EER	9.2030e-06	0.1979
chr7:128502640-128506122:+	READ	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	1.0399e-02	0.2618
ENSG00000165055.14,METTL2B	READ	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	1.0399e-02	0.2618
ENSG00000165055.14,METTL2B	SARC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	2.8713e-05	-0.2588
chr7:128502640-128506122:+	SARC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	2.0945e-05	-0.2630
chr7:128502640-128506122:+	SKCM	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	3.4474e-06	0.2129
ENSG00000165055.14,METTL2B	SKCM	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	6.2655e-06	0.2073
chr7:128502640-128506122:+	STAD	GSVA_HALLMARK_PROTEIN_SECRETION	EER	6.3741e-06	0.2325
ENSG00000165055.14,METTL2B	STAD	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	3.0505e-04	0.1870
chr7:128502640-128506122:+	TGCT	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	8.9943e-05	0.3084
ENSG00000165055.14,METTL2B	TGCT	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.3430e-04	0.3010
ENSG00000165055.14,METTL2B	THCA	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	1.9569e-08	0.2471
chr7:128502640-128506122:+	THCA	GSVA_HALLMARK_ANDROGEN_RESPONSE	EER	1.0747e-08	0.2515
ENSG00000165055.14,METTL2B	THYM	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	9.9356e-09	0.4975
chr7:128502640-128506122:+	THYM	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	9.8197e-09	0.4977
chr7:128502640-128506122:+	UCEC	GSVA_HALLMARK_PROTEIN_SECRETION	EER	4.4304e-07	0.3707
ENSG00000165055.14,METTL2B	UCEC	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	6.1681e-05	0.2972
chr7:128502640-128506122:+	UCS	GSVA_HALLMARK_DNA_REPAIR	EER	4.6999e-02	-0.2666
ENSG00000165055.14,METTL2B	UVM	GSVA_HALLMARK_E2F_TARGETS	EAG	2.4751e-04	-0.4429
chr7:128502640-128506122:+	UVM	GSVA_HALLMARK_E2F_TARGETS	EER	2.4751e-04	-0.4429

Top

7. Enriched editing regions and drugs for METTL2B

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000165055.14,METTL2B	ACC	ATRA	EAG	1.2423e-02	0.2893
chr7:128502640-128506122:+	ACC	ATRA	EER	1.2608e-02	0.2887
ENSG00000165055.14,METTL2B	BLCA	Embelin	EAG	3.3234e-07	-0.2513
chr7:128502640-128506122:+	BLCA	Embelin	EER	1.9263e-07	-0.2561
chr7:128502640-128506122:+	BRCA	CCT007093	EER	2.1484e-12	-0.2118
ENSG00000165055.14,METTL2B	BRCA	CCT007093	EAG	4.9897e-13	-0.2173
chr7:128502640-128506122:+	CESC	JNK.Inhibitor.VIII	EER	1.7812e-05	-0.2442
ENSG00000165055.14,METTL2B	CESC	JNK.Inhibitor.VIII	EAG	2.1154e-05	-0.2420
chr7:128502640-128506122:+	CHOL	GW843682X	EER	2.4520e-02	0.3796
ENSG00000165055.14,METTL2B	CHOL	GW843682X	EAG	2.4520e-02	0.3796
ENSG00000165055.14,METTL2B	COAD	CCT007093	EAG	9.9299e-09	-0.3400
chr7:128502640-128506122:+	COAD	CCT007093	EER	5.7425e-06	-0.2735
ENSG00000165055.14,METTL2B	DLBC	BI.D1870	EAG	4.0699e-03	0.4114
chr7:128502640-128506122:+	DLBC	BI.D1870	EER	7.3979e-03	0.3858
chr7:128502640-128506122:+	ESCA	JNJ.26854165	EER	6.1217e-03	-0.2158
ENSG00000165055.14,METTL2B	ESCA	JNJ.26854165	EAG	2.1245e-02	-0.1820
chr7:128502640-128506122:+	GBM	KU.55933	EER	7.7589e-03	-0.2054
ENSG00000165055.14,METTL2B	GBM	KU.55933	EAG	8.4954e-03	-0.2030
chr7:128502640-128506122:+	HNSC	AZD6482	EER	4.0560e-07	-0.2267
ENSG00000165055.14,METTL2B	HNSC	AZD6482	EAG	4.6679e-07	-0.2255
ENSG00000165055.14,METTL2B	KICH	Methotrexate	EAG	1.7024e-02	-0.2951
chr7:128502640-128506122:+	KICH	Methotrexate	EER	1.7024e-02	-0.2951
chr7:128502640-128506122:+	KIRC	AKT.inhibitor.VIII	EER	3.5092e-04	-0.1827
ENSG00000165055.14,METTL2B	KIRC	DMOG	EAG	4.5417e-04	-0.1790
ENSG00000165055.14,METTL2B	KIRP	AZD6244	EAG	1.6352e-06	0.2795
chr7:128502640-128506122:+	KIRP	AZD6244	EER	1.4509e-06	0.2809
ENSG00000165055.14,METTL2B	LAML	AZD6244	EAG	1.0519e-02	-0.2730
chr7:128502640-128506122:+	LGG	BMS.708163	EER	6.0521e-08	-0.2328
ENSG00000165055.14,METTL2B	LGG	BMS.708163	EAG	5.7300e-08	-0.2332
chr7:128502640-128506122:+	LIHC	IPA.3	EER	2.4485e-07	0.2655
ENSG00000165055.14,METTL2B	LIHC	IPA.3	EAG	2.8300e-07	0.2641
ENSG00000165055.14,METTL2B	LUAD	BMS.708163	EAG	1.8920e-05	-0.1891
chr7:128502640-128506122:+	LUAD	BMS.708163	EER	1.5141e-05	-0.1914
ENSG00000165055.14,METTL2B	LUSC	AICAR	EAG	5.7490e-04	-0.1550
chr7:128502640-128506122:+	LUSC	AICAR	EER	4.2738e-04	-0.1587
chr7:128502640-128506122:+	MESO	AZD.0530	EER	1.1213e-02	-0.2788
ENSG00000165055.14,METTL2B	MESO	AZD.0530	EAG	9.7308e-03	-0.2840
ENSG00000165055.14,METTL2B	OV	CMK	EAG	2.2751e-03	-0.1779
chr7:128502640-128506122:+	OV	CMK	EER	1.6744e-03	-0.1831
ENSG00000165055.14,METTL2B	PAAD	GDC.0449	EAG	4.6190e-05	-0.3072
chr7:128502640-128506122:+	PAAD	GDC.0449	EER	4.8510e-05	-0.3063
ENSG00000165055.14,METTL2B	PCPG	Gefitinib	EAG	4.1582e-05	0.2981
chr7:128502640-128506122:+	PCPG	Gefitinib	EER	4.4305e-05	0.2971
ENSG00000165055.14,METTL2B	PRAD	CEP.701	EAG	2.4150e-04	0.1643
chr7:128502640-128506122:+	PRAD	CEP.701	EER	1.5044e-04	0.1696
ENSG00000165055.14,METTL2B	READ	AG.014699	EAG	2.8432e-05	-0.4154
chr7:128502640-128506122:+	READ	AG.014699	EER	2.8432e-05	-0.4154
ENSG00000165055.14,METTL2B	SARC	AZD6482	EAG	9.3559e-10	-0.3713
chr7:128502640-128506122:+	SARC	AZD6482	EER	5.8252e-10	-0.3755
chr7:128502640-128506122:+	SKCM	CGP.082996	EER	5.7351e-05	-0.1851
ENSG00000165055.14,METTL2B	SKCM	CGP.082996	EAG	7.5941e-05	-0.1821
ENSG00000165055.14,METTL2B	STAD	BMS.754807	EAG	1.7258e-04	0.1943
chr7:128502640-128506122:+	STAD	BMS.754807	EER	6.0285e-04	0.1778
chr7:128481649-128482400:+	STAD	AKT.inhibitor.VIII	EER	2.7732e-02	-0.2710
chr7:128502640-128506122:+	TGCT	AZD6482	EER	4.7504e-05	-0.3196
ENSG00000165055.14,METTL2B	TGCT	AZD6482	EAG	1.0466e-04	-0.3056
ENSG00000165055.14,METTL2B	THCA	AMG.706	EAG	4.4734e-08	0.2409
chr7:128502640-128506122:+	THCA	AMG.706	EER	3.5265e-08	0.2427
ENSG00000165055.14,METTL2B	THYM	CEP.701	EAG	3.4810e-12	0.5850
chr7:128502640-128506122:+	THYM	CEP.701	EER	3.1892e-12	0.5859
chr7:128502640-128506122:+	UCEC	AMG.706	EER	9.8741e-06	0.3272
ENSG00000165055.14,METTL2B	UCEC	AZD6482	EAG	2.3088e-05	-0.3132
ENSG00000165055.14,METTL2B	UCS	BI.2536	EAG	1.4001e-02	0.3267
chr7:128502640-128506122:+	UCS	BI.2536	EER	1.1400e-02	0.3358
ENSG00000165055.14,METTL2B	UVM	AP.24534	EAG	2.0838e-03	-0.3778
chr7:128502640-128506122:+	UVM	AP.24534	EER	2.0838e-03	-0.3778

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType